

DIAGNOSTIC METHOD FOR DEMENTIA WITH LEWY BODIES

Genetic biomarkers for the early identification of patients suffering from dementia with Lewy bodies

OVERVIEW



Dementia with Lewy bodies (DLB) is the result of **abnormal α -synuclein aggregation and accumulation** in form of Lewy bodies causing neuronal cell death.

DLB is the **second most common neurodegenerative dementia after Alzheimer's Disease (AD)** in people older than 65 years. In these populations, the incidence of DLB is reported between 0.5-1.6/1.000 person/year accounting for at least 5% of dementias cases.

DLB is an aggressive disease with a reported **average survival of 4.7-year** but is frequently mistaken for other degenerative dementias, most often AD.



PROJECT

Sector: Central Nervous system

R&D direction:

Diagnosis of DLB

Stage of development: TRL2-3

Scientific leader: Dr. Katrin Beyer

Clinical Advisor: Dr. Ramiro Álvarez



PRODUCT

Potential indications:

Diagnosis of DLB at early stages

Diagnosis of prodromal DLB patients

Monitoring DLB progression

Mechanism of action:

Circulating biomarkers test

Market size: 140K tests per year

Market value: €14M per year



IP PROTECTION

Patent Granted



OPPORTUNITY

License out

Spin-off



NEEDS

Until now, there are neither reliable biomarkers for the early diagnosis of DLB, nor disease-modifying therapies have been developed. Although α -synuclein anti-aggregatory agents are under development no biomarkers to monitor their outcome have been identified.

Therefore, there is an **urgent need of biomarkers for both early DLB diagnosis and monitoring α -synuclein anti-aggregatory therapies.**



SOLUTION

Our project proposes to create a biomarker signature:

- for **early DLB diagnosis** based on the expression levels of 5 SNCA (α -synuclein) transcripts
- to monitor the efficiency of **α -synuclein anti-aggregatory therapies** in DLB patients, based on the expression levels of one SNCA transcript



KEY ADVANTAGES

- Easily accessible and minimally invasive: from blood samples
- Quick and non-expensive
- Allows disease confirmation: high accuracy
- Specificity over 90%
- Shortens time to diagnosis
- Monitors disease progression and treatment efficacy
- Inclusion in clinical trials to prevent or delay the onset of the disease

CONTACT US!

innovation@igtp.cat

Innovation & Business Development Unit